## A: Agilent Technologies, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -2.0% below STRENGTH zone (3.0-6.0%); PEG 2.13 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($132.00)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 7
- **Sentiment:** Bullish (Bullish: 1, Bearish: 0)

**1. AGILENT TECHNOLOGIES, INC. SEC 10-K Report**
- Source: TradingView â€” Track All Markets | 20251222T110749 | Neutral | Relevance: 100%
- Agilent Technologies, Inc. has released its 2025 10-K report, highlighting a 7% increase in total net revenue to $6,948 million, despite a decrease in gross and operating margins. The company restructured into three segments: Life Sciences and Diagnostics, Agilent CrossLab, and Applied Markets, to enhance operational efficiency and customer focus. Strategic initiatives include a restructuring plan to reduce costs, a new share repurchase program, and ongoing investments in R&D, while facing challenges from global operations, economic instability, and regulatory changes.

**2. Agilent Technologies opens India refurbishment center to promote sustainable science**
- Source: FoodTechBiz | 20251222T050759 | Bullish | Relevance: 100%
- Agilent Technologies has inaugurated its India Refurbishment Center and India Education Center in Manesar, Haryana, to promote sustainable science and affordability. The facility will provide Certified Pre-Owned instruments and hands-on training, reinforcing Agilent's commitment to the Indian market. This initiative aims to support laboratories with cost-effective solutions and empower customers with advanced tools while adhering to environmentally responsible practices.

**3. Osaic Holdings Inc. Has $8.02 Million Stock Position in Agilent Technologies, Inc. $A**
- Source: MarketBeat | 20251222T110354 | Somewhat-Bullish | Relevance: 100%
- Osaic Holdings Inc. significantly increased its stake in Agilent Technologies, Inc. during the second quarter, now holding 68,053 shares valued at $8.02 million. This comes as Agilent reported strong quarterly earnings, beat analyst expectations, and raised its dividend, signaling positive financial health. Despite institutional buying, company insiders have recently been net sellers, disposing of over $2.4 million worth of stock.

**4. Perpetual Ltd Lowers Stock Position in Agilent Technologies, Inc. $A**
- Source: MarketBeat | 20251221T110926 | Somewhat-Bullish | Relevance: 100%
- Perpetual Ltd significantly reduced its stake in Agilent Technologies (NYSE:A) by 54.8% in Q3 2025, selling 16,677 shares. Despite this, other major institutions like Vanguard, Massachusetts Financial Services Co., Geode Capital Management LLC, Generation Investment Management LLP, and UBS AM increased their holdings. Analyst sentiment remains largely positive, with a consensus "Moderate Buy" rating and several firms raising their price targets for Agilent Technologies.

**5. Texas Permanent School Fund Corp Trims Stake in Agilent Technologies, Inc. $A**
- Source: MarketBeat | 20251221T102934 | Somewhat-Bullish | Relevance: 100%
- Texas Permanent School Fund Corp significantly reduced its stake in Agilent Technologies, Inc. (NYSE:A) by 60.3% in the second quarter, selling 30,499 shares and retaining 20,054 shares valued at $2.37 million. This move aligns with a trend of insider selling, as company executives, including the CEO and a VP, have sold a total of 16,401 shares worth approximately $2.47 million in the last 90 days. Despite the institutional selling, Agilent Technologies reported slightly better-than-expected Q results, raised its quarterly dividend, and provided optimistic FY2026 guidance, while analysts maintain a "Moderate Buy" consensus rating with a target price of $161.77.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 7, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-15 | Barclays | $165 | $165 | 0% |
| 2025-12-09 | Goldman Sachs | $170 | $0 | 0% |
| 2025-12-02 | Morgan Stanley | $180 | $0 | 0% |
| 2025-11-25 | Citigroup | $185 | $165 | +12% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-15 | Barclays | up | Overweight |
| 2025-12-09 | Goldman Sachs | init | Buy |
| 2025-12-02 | Morgan Stanley | init | Overweight |
| 2025-11-25 | Citigroup | main | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 10 ($1.37M) |
| Sells | 18 ($1.60M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 44.9% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 12.0% (+0.1%)
- Blackrock Inc.: 9.2% (+1.0%)
- Massachusetts Financ: 4.4% (-6.0%)
- State Street Corpora: 4.4% (-0.1%)
- Wellington Managemen: 3.3% (+4.8%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Analyst target momentum: 7 raises (avg +12%) could attract flows.
- AI/machine learning initiatives could drive multiple expansion if executed.

### Fundamentals

PEG ratio 2.13 elevated, pricing in significant growth expectations. Forward P/E 21.1x stretched relative to 10% growth. Quality metrics strong (ROE 21%, margin 19%). Analyst sentiment positive (7 raises, avg +12%). Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $39.2B |
| Beta | 1.27 |
| 52W Range | $96.43 - $160.27 |
| Short Interest | 1.3% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 2.13 |
| Forward P/E | 21.1 |
| Current P/E | 23.3 |
| YoY Growth | 10.3% |
| EPS Direction | STABLE |

### Technicals

MRS_10 deteriorating from -0.9% to -2.0% (-1.1% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 5.0pp (needs >3.0% for momentum thesis). Long-term uptrend intact (above SMA200 at 1.11x) but short-term weakness (below SMA20). MACD histogram bearish (-0.81), momentum weakening. OFD pattern: +SBL (Volatile).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -1.98% (CS: 30) | Neutral |
| RSI_14 | 39.5 | Neutral |
| MACD Histogram | -0.81 | Bearish |
| vs SMA20 | 0.960x | Below |
| vs SMA50 | 0.954x | Below |
| vs SMA200 | 1.111x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $138.36
- **Stop Loss:** $132.00 (4.6% risk)
- **Target:** $144.72 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 188
- **Position Value:** $26,011.68
- **Portfolio %:** 26.01%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 120% | L2 100% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderate risk appetite in holiday-thinned conditions. VIX at 52-week lows suggests complacency, but modest breadth improvement and stable yields indicate underlying stability. Focus on quality positioning ahead of 2026 catalysts.*

### Earnings

**Next:** 2026-02-25 (Est: $1.37)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q4 | $1.58 | $1.59 | +0.4% |
| 2025Q3 | $1.37 | $1.37 | +0.2% |
| 2025Q2 | $1.26 | $1.31 | +3.6% |
| 2025Q1 | $1.27 | $1.31 | +3.0% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*